Please login to the form below
axicabtagene ciloleucel
This page shows the latest axicabtagene ciloleucel news and features for those working in and with pharma, biotech and healthcare.
GSK pays $50m upfront to tap Immatics’ cell therapy platform
Moreover, unlike currently-approved CAR-T therapies for cancer like Novartis’ Kymriah (tisagenlecleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) which are approved for haematologic cancers, TCRs has the potential to
Latest news
-
FDA begins speedy review of BMS’ CAR-T liso-cel
If it does receive approval, liso-cel will come onto the market after rival Novartis’ Kymriah (tisangenlecleucel) and Gilead Sciences’ Yescarta (axicabtagene ciloleucel).
-
FDA starts priority review of Kite’s CAR-T for mantle cell lymphoma
Gilead/Kite’s approved CAR-T therapy Yescarta (axicabtagene ciloleucel) is available for the treatment of diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma.
-
EMA begins review of Kite’s CAR-T for mantle cell lymphoma
Gilead/Kite already have one approved CAR-T therapy in the arsenal – Yescarta (axicabtagene ciloleucel) – which is approved for diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma.
-
Incyte signs lymphoma deal worth up to $1.1bn with MorphoSys
If approved, tafasitamab will go on to compete with existing cancer drugs including CAR-T therapies like Novartis’ Kymriah (tisagenlecleucel) and Gilead’s Yescarta (axicabtagene ciloleucel).
-
Gilead owes BMS millions after losing Yescarta patent infringement trial
Gilead has been ordered to pay BMS $585m in damages, plus a 27.6% running royalty on all sales of Yescarta (axicabtagene ciloleucel).
More from news
Approximately 1 fully matching, plus 39 partially matching documents found.
Latest Intelligence
-
The European Medicines Agency: PRIME’d for access?
Early signs are looking good: Novartis’ Kymriah (tisagenlecleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) secured positive opinions from EMA's Committee for Medicinal Products for Human Use (CHMP) in June
-
Deal Watch January 2017
Kite Pharma. Daiichi Sankyo. Licence. Cellular cancer therapy axicabtagene ciloleucel (KTE-C19).
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- China’s CanSino Biologics reveals phase 2 coronavirus vaccine results
- How will the events and exhibitions industry change post-Coronavirus?
- AbbVie, Roche’s Venclyxto combo reduces risk of death in first-line AML
- Eli Lilly begins COVID-19 prevention trial in nursing homes
- Russia becomes first country to approve a COVID-19 vaccine
- Tecentriq combo fails in advanced triple negative breast cancer
- UK agrees on COVID-19 vaccine deals with J&J and Novavax
- COVID-19 vaccine approval unlikely before November, says US NIH director
- Calliditas bets on PBC drug in Genkyotex buyout
- Emotion-driven clinical trial marketing: A missed opportunity?
- Speed kills
- Unleashing the Potential of Multichannel Digital Strategies in Healthcare
PMHub
Purple Agency
An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....
Latest intelligence
- Emotion-driven clinical trial marketing: A missed opportunity?
- Whether we’re conscious of it or not, our emotions play a huge role in day-to-day decision making. Psychological scientists have long explored emotional influences on decision making. Experts like Herbert...
- Virtual Hackathon on Healthcare Innovation: a Customer Story
- How participants from 9 different countries in the APAC region were brought together to participate in a pharmaceutical company-wide 3-day virtual "hackathon," with spectacular results....
- OPEN Health at the World Orphan Drug Conference USA
- Our Director of Rare Disease, Gavin Jones looks forward to his conversation with Emily Crossle & Betsy Bogard at #WODCUSA2020 !...
Quick links
Infographics
